Elsevier

Journal of Infection

Volume 70, Issue 4, April 2015, Pages 367-380
Journal of Infection

Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB

https://doi.org/10.1016/j.jinf.2014.12.018Get rights and content

Highlights

  • Increased age is a risk factor for false-negative T-SPOT.TB results in PTB and EPTB.

  • Over-weight is a risk factor for false-negative T-SPOT.TB results in PTB.

  • Longer period of illness is a risk factor for false-negative T-SPOT.TB in PTB.

  • PTB and EPTB are different in the risk factors for false-negative T-SPOT.TB results.

Summary

Objectives

To investigate the risk factors for false-negative T-SPOT.TB results in patients with pulmonary TB (PTB) and extra-pulmonary TB (EPTB).

Methods

Patients with suspected TB who underwent valid T-SPOT.TB tests were prospectively enrolled at Beijing Chest Hospital between November 2012 and November 2013. Basic characters and clinical laboratory findings were compared between true-positive and false-negative T-SPOT.TB groups.

Results

Of 1928 suspected TB patients, 774 (530 PTB and 244 EPTB) microbiologically/histopathogenically-confirmed patients (636 culture-confirmed) were analyzed. Forty-six PTB patients (8.7%) and 32 EPTB patients (13.1%) had negative T-SPOT.TB results. Multivariate analysis showed that increased age [odds radio (OR) 2.26, 95% confidence interval (CI) 1.11–4.58], over-weight (BMI ≥ 25 kg/m2, OR 2.43, 95% CI 1.05–5.63), and a longer period of illness before hospitalization (>6 months, OR 2.46, 95% CI 1.24–4.92) were independent risk factors for false-negative T-SPOT.TB results in PTB patients. In EPTB patients, increased age (OR 2.42, 95% CI 1.09–5.35) also showed an independent association with false-negative T-SPOT.TB results.

Conclusion

Careful interpretation of negative T-SPOT.TB results is necessary in older patients with suspected PTB or EPTB, and in PTB patients who are over-weight or have had longer periods of illness before hospitalization.

Introduction

Tuberculosis (TB) is a major global infectious disease causing high mortality and morbidity, with 1.3 million deaths and 8.6 million new cases estimated by WHO each year worldwide.1 It shows a marked regional diversity and has highest prevalence in the South East Asian region (India), followed by the Western Pacific region (China and philippines).1 Early diagnosis and treatment are critical strategies for TB control in these high-burden developing countries. However, the definitive diagnostic methods, including the culture of Mycobacterium tuberculosis (M.TB) bacteria from sputum samples and smear of acid-fast bacilli, demonstrate some limitations in identifying all TB cases.2 Other adjunctive diagnostic methods, such as tuberculin skin tests, radiography, and nucleic acid amplification tests, exhibit poorer performances in diagnosis of active TB.3, 4 Moreover, the non-specific clinical presentations of extra-pulmonary TB (EPTB), and its paucibacillary load in poorly accessible sites of affected organs results in a lower chance of establishing a definitive diagnosis.5

Recently, interferon-gamma release assays (IGRAs) that detect IFN-γ responses to M. tuberculosis-specific antigens, including an enzyme-linked immunospot assay (T-SPOT.TB, Oxford Immunotec, UK) and the whole blood enzyme-linked immunosorbent assay (QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube, QFT-TB, Cellestis Ltd, Australia) have been shown to be valid methods for detecting M.TB infection, due to their lack of cross-reactivity with bacillus Calmette–Guerin (BCG) and most non-tuberculous mycobacteria (NTM).6 However, the performances of these two commercial assays in the diagnosis of active TB have varied among populations and methods. Meta-analyses have shown that the overall sensitivity of T-SPOT.TB and QFT-TB for diagnosing active TB have ranged from 60% to 89%.7, 8, 9, 10, 11, 12 Meta-analysis focusing on pulmonary TB (PTB) diagnosis showed a sensitivity of 88% and 84% for T-SPOT.TB and QFT-TB,13 while 90% and 72% for EPTB in another meta-analysis.14

Some studies have recommended the use of IGRAs as an adjunct tool for diagnosis of active TB.7, 15, 16, 17, 18, 19, 20 However, its imperfect sensitivity may be a potential problem in interpreting negative IGRA results in suspected TB patients. Investigation of the factors that lower the sensitivity of IGRAs would facilitate better interpretation of IGRA results. Ethnicity has been reported as a risk factor for decreased sensitivity of the IGRAs test, the sensitivity of IGRAs in Malay and India patients were diminished compared to Chinese patients.21 It has previously been shown that HIV co-infection, immune suppression, increased age, body mass index (BMI), advanced disease, lymphocytopenia, and HLA-genotype are related to false-negative results in the QFT-TB assay, in different clinical settings.22, 23, 24, 25, 26 T-SPOT.TB assay is based on the ELISpot method, while QFT-TB assay is based on the ELISA method. This methodological difference may be the reason for the discordant sensitivities of these two assays, and may also suggest that factors which decrease sensitivity in these two assays are different. Up to date, only one study has found that increased age and steroid use were associated with false-negative T-SPOT.TB results in active TB,27 while another study found that TB meningitis is associated with false-negative T-SPOT.TB results in EPTB.28 Considering the limited information available on the risk factors associated with false-negative T-SPOT.TB results, we performed a prospective study to comprehensively explore the potential factors, including clinical characteristics and laboratory findings, which may influence T-SPOT.TB results in both microbiologically/histopathologically-confirmed pulmonary and extra-pulmonary TB.

Section snippets

Study population

This prospective study was conducted at the Beijing Chest Hospital (Beijing, China), a specialist tuberculosis and thoracic tumor disease clinic with a capacity of 533 beds. Between November 2012 and November 2013, a total of 1928 suspected TB patients who underwent valid T-SPOT.TB assays before the onset of anti-TB therapy were enrolled in the study. Patients gave written informed consent and were included if they had any clinical symptoms, signs or radiographic evidence of active TB. Patients

Clinical characteristics of participants

Among the 1928 patients suspected of TB prior to anti-TB therapy who underwent valid T-SPOT.TB tests, 774 (40.1%) patients were diagnosed as having microbiologically/histopathologically-confirmed TB, 209 (10.8%) patients were diagnosed as having no active TB, and 945 (49.1%) patients as having clinical TB. Only the 774 (40.1%) patients with microbiologically/histopathologically-confirmed TB were included for further analysis (Fig. 1). Among these patients, 554 patients were microbiologically

Discussion

Imperfect sensitivity gives rise to potential problems when using negative IGRA results as a ruling-out criteria in the diagnosis of active TB. Investigation of risk factors that decrease the sensitivity of IGRAs facilitates better interpretation of IGRA results. Previous studies investigating risk factors for false-negative IGRA results mainly focused on the QFT-TB test,22, 23, 24, 25, 26 with only two studies investigating the T-SPOT.TB test.27, 28 Information available on factors leading to

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Acknowledgments

We thank all the subjects who participated in this study. This work was supported by grants from the National Science and Technology Major Project of China (No. 2013ZX10003003-004 and 2015ZX10004801-003), the Collaborative Innovation Center of Infectious Diseases (No. PXM2014_014226_000011), and the Beijing Outstanding Talent Training Project (No. 2013D003034000038).

References (82)

  • Y. Kobashi et al.

    Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis

    Chest

    (2008)
  • J.E. Lee et al.

    The clinical utility of tuberculin skin test and interferon-gamma release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study

    BMC Infect Dis

    (2011)
  • S.M. Tavares et al.

    Normal lymphocyte immunophenotype in an elderly population

    Rev Bras Hematol Hemoter

    (2014)
  • D.C. Nieman et al.

    Influence of obesity on immune function

    J Am Diet Assoc

    (1999)
  • J.Y. Jung et al.

    Questionable role of interferon-gamma assays for smear-negative pulmonary TB in immunocompromised patients

    J Infect

    (2012)
  • G. Ferrara et al.

    Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

    Lancet

    (2006)
  • C.C. Lai et al.

    Diagnostic performance of whole-blood interferon-gamma assay and enzyme-linked immunospot assay for active tuberculosis'

    Diagn Microbiol Infect Dis

    (2011)
  • J.Y. Lee et al.

    Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection

    Eur Respir J

    (2006)
  • J. Chen et al.

    T-SPOT.TB in the diagnosis of active tuberculosis among HIV-infected patients with advanced immunodeficiency

    AIDS Res Hum Retrovir

    (2011)
  • S.J. Jeong et al.

    Predictive factors for indeterminate result on the QuantiFERON test in an intermediate tuberculosis-burden country

    J Infect

    (2011)
  • World Health Organization, Global Tuberculosis Report

    (2013)
  • M. Pai et al.

    Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

    Ann Intern Med

    (2008)
  • L. Norbis et al.

    Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis

    Expert Rev Anti Infect Ther

    (2014)
  • R. Diel et al.

    Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis

    Eur Respir J

    (2011)
  • J. Chen et al.

    Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: a systematic review and meta-analysis

    PLoS One

    (2011)
  • Y. Dai et al.

    Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis

    Eur J Clin Microbiol Infect Dis

    (2012)
  • K. Dheda et al.

    T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings

    Curr Opin Pulm Med

    (2009)
  • M. Santin et al.

    Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis

    PLoS One

    (2012)
  • M. Sester et al.

    Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis

    Eur Respir J

    (2011)
  • J.Z. Metcalfe et al.

    Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis

    J Infect Dis

    (2011)
  • L. Fan et al.

    Interferon-gamma release assays for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis

    FEMS Immunol Med Microbiol

    (2012)
  • Y. Kobashi et al.

    Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis

    Intern Med

    (2008)
  • Y. Feng et al.

    Interferon-gamma release assay performance in pulmonary and extrapulmonary tuberculosis

    PLoS One

    (2012)
  • C.B. Chee et al.

    Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis

    J Clin Microbiol

    (2008)
  • N.T. Hang et al.

    Analysis of factors lowering sensitivity of interferon-gamma release assay for tuberculosis

    PLoS One

    (2011)
  • C. Kiwon et al.

    Factors associated with indeterminate and false negative results of QuantiFERON-TB Gold In-Tube test in active tuberculosis

    Tuberc Respir Dis

    (2012)
  • Y. Kobashi et al.

    False negative results of QuantiFERON TB-2G test in patients with active tuberculosis

    Jpn J Infect Dis

    (2009)
  • Y.M. Lee et al.

    Risk factors for false-negative results of T-SPOT.TB and tuberculin skin test in extrapulmonary tuberculosis

    Infection

    (2013)
  • D. Bumbacea et al.

    The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement

    Eur Respir J

    (2012)
  • F. Cantini et al.

    Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-alpha (TNF-alpha) targeted biologics and recently licensed TNF-alpha inhibitors: data from clinical trials and national registries

    J Rheumatol Suppl

    (2014)
  • D. Goletti et al.

    Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches

    J Rheumatol Suppl

    (2014)
  • Cited by (74)

    • High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase III, multi-centered, double-blind, hospital-based, randomized controlled trial

      2023, International Journal of Infectious Diseases
      Citation Excerpt :

      However, since the ECST is responsive to latent infection, it is more likely to be used as a TB infection rule-out test rather than a decision-making test for active TB. The finding that the diagnostic accuracy of ECST was better in younger groups (Figure 2) was similar to studies of IGRAs and TST (Almeida Santos et al., 2020; Pan et al., 2015). This may be because younger people are more immunocompetent than the elderly and, consequently, are less likely to present negative results.

    • The diagnostic value of an interferon gamma release assay in new cases of active pulmonary tuberculosis and the factors influencing its negative results

      2023, Medicina Clinica Practica
      Citation Excerpt :

      In this study, several factors related to the false-negative results of QFT-GIT were reported, which helped to explain why some patients presented with characteristics of BC-PTB in clinical practice but obtained negative results of QFT-GIT to some extent. The state of severe immunosuppression, long-term use of immunosuppressants or glucocorticoids, diabetes or malignant tumors, age, gender, BMI and other factors were demonstrated to be reasonable for the false-negative results of QFT-GIT.5,9–14 In our study,overweight, complicated with diabetes, malignant tumors, or severe infections were found to be independent risk factors of false-negative results of QFT-GIT.

    • High-resolution imaging of protein secretion at the single-cell level using plasmon-enhanced FluoroDOT assay

      2022, Cell Reports Methods
      Citation Excerpt :

      Despite its enormous utility, this method has not undergone significant technological advances in spatial resolution or sensitivity over the past 3 decades. ELISpot assays thus remain severely limited by the inability to spatially resolve protein secretion, discrepancies in assay readout, and false negatives in clinical diagnosis (Janetzki et al., 2015; Pan et al., 2015). We introduce a simple yet powerful ultraresolved digital version of ELISpot and FluoroSpot assays called the FluoroDOT assay.

    View all citing articles on Scopus
    View full text